Regeneron Pharmaceuticals said it has filed an application with the FDA seeking emergency use authorization for the experimental antibody cocktail used to treat President Donald Trump for COVID-19. If granted an EUA, the company said it has doses for 50,000 people available and expects to be able to treat 300,000 within a few months.
Regeneron seeks EUA for antibody cocktail
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.